.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Amikacin remains a cornerstone in treating severe infections. However, a recent study highlights a potential breakthrough using the Roflumilast renoprotective effect to mitigate toxicity. Researchers investigated how this selective PDE4 inhibitor shields the kidneys from drug-induced injury.
The study utilized a rat model to evaluate kidney function after amikacin exposure. Results showed that amikacin significantly elevated serum creatinine and blood urea nitrogen levels. In contrast, Roflumilast co-treatment restored these markers toward baseline. Furthermore, the drug activated the Nrf2/HO-1 signaling pathway. This activation is vital because it upregulates antioxidant enzymes like SOD and catalase. Consequently, the drug successfully neutralized lipid peroxidation and oxidative stress.
Amikacin typically triggers a severe inflammatory response through the NF-κB cascade. Moreover, Roflumilast co-administration suppressed this pathway, leading to lower levels of cytokines like TNF-α and IL-1β. In addition, the treatment modulated apoptotic markers. It reduced pro-apoptotic proteins like Bax and Caspase-3 while increasing anti-apoptotic Bcl-2 expression. Histopathological evaluations confirmed these biochemical findings. Therefore, Roflumilast could become a vital therapeutic strategy for patients requiring aminoglycoside therapy.
Roflumilast primarily protects the kidneys by activating the Nrf2/HO-1 antioxidant pathway. This helps the body neutralize harmful reactive oxygen species caused by drugs like amikacin.
Yes, Roflumilast inhibits the NF-κB inflammatory cascade. This reduction leads to lower levels of pro-inflammatory cytokines, which helps prevent tissue damage during amikacin treatment.
While Roflumilast is approved for COPD, its use for renoprotection is currently being explored in preclinical studies. Further clinical trials are needed to confirm these effects in humans.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Abdel-Kareem MA et al. Renoprotective effect of roflumilast against amikacin- induced nephrotoxicity: upregulation of Nrf2 signaling, inhibition of cytokines, and renal apoptosis. Drug Chem Toxicol. 2026 Jun 22. doi: 10.1080/01480545.2026.2657439. PMID: 42325070.
Man et al. Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2020 Mar 1;318(3):F776-F788. doi: 10.1152/ajprenal.00477.2019.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent study demonstrates that Roflumilast, a PDE4 inhibitor, provides a significant renoprotective effect against amikacin-induced nephrotoxicity by upregulating Nrf2 signaling and suppressing inflammatory and apoptotic pathways.
2 months ago
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
Last week
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
4 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
4 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
Last week
